Antiviral agent 80

Antiviral agent 80 (Compound 7j) exhibits potent inhibitory activity against both wild-type and drug-resistant influenza neuraminidase (NA) mutants, with IC₅₀ values ranging from 1.50 nM to 120.4 nM. Specifically, its IC₅₀ values against N9, N1, and N1 (H275Y) are 1.5 nM, 1.69 nM, and 2.05 nM, respectively^[1].
Antiviral agent 80 protects MDCK cells from influenza A virus-induced cytopathic effects, with an EC₅₀ value ranging from 11.13 nM to 12.55 nM and a CC₅₀ greater than 200 μM, indicating high selectivity^[1].
Antiviral agent 80 (5 μM; 24 h) induces proteasome-dependent NA degradation in HEK293T cells transfected with NA plasmid, with a degradation rate of approximately 95%; it does not upregulate autophagy markers in BEAS-2B, HEK293T or A549 cells^[1].
Antiviral agent 80 can efficiently cross cell membranes and accumulate in MDCK cells, with intracellular retention rates of 88.8% and 19.1% at pretreatment concentrations of 100 μM and 25 μM, respectively; after removing extracellular compounds by washing, its EC₅₀ against A/WSN/1933 only slightly increases from 11.13 nM to 48.0 nM, indicating that this compound possesses strong intracellular antiviral activity^[1].
Antiviral agent 80 inhibits multiple stages of the influenza A virus life cycle in MDCK cells, which is evidenced by the reduction in M1 protein levels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.